Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Carol Epstein, MD
MediVector, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
247 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
La Palta, Buenos Aires, Argentina
- Facility name not stated
Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
- Facility name not stated
Córdoba, Córdoba Province, Argentina
- Facility name not stated
Córdoba, Córdoba Province, Argentina
- Facility name not stated
Rosario, Santa Fe Province, Argentina
- Facility name not stated
Santa Fe, Santa Fe Province, Argentina
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Mar del Plata, Argentina
- Facility name not stated
Ramos Mejía, Argentina
- Facility name not stated
San Miguel de Tucumán, Argentina
- Facility name not stated
Vicente López, Argentina
- Facility name not stated
Belo Horizonte, Minas Gerais, Brazil
- Facility name not stated
Juiz de Fora, Minas Gerais, Brazil
- Facility name not stated
Curitiba, Paraná, Brazil
- Facility name not stated
Passo Fundo, Rio Grande do Sul, Brazil
- Facility name not stated
Porto Alegre, Rio Grande do Sul, Brazil
- Facility name not stated
Porto Alegre, Rio Grande do Sul, Brazil
- Facility name not stated
Campinas, São Paulo, Brazil
- Facility name not stated
Santo André, São Paulo, Brazil
- Facility name not stated
Santo André, São Paulo, Brazil
- Facility name not stated
São Paulo, São Paulo, Brazil
- Facility name not stated
São Paulo, São Paulo, Brazil
- Facility name not stated
São Paulo, São Paulo, Brazil
- Facility name not stated
Brasília, Brazil
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Mount Pearl, Newfoundland and Labrador, Canada
- Facility name not stated
St. John's, Newfoundland and Labrador, Canada
- Facility name not stated
Burlington, Ontario, Canada
- Facility name not stated
Cambridge, Ontario, Canada
- Facility name not stated
Corunna, Ontario, Canada
- Facility name not stated
Hamilton, Ontario, Canada
- Facility name not stated
London, Ontario, Canada
- Facility name not stated
Newmarket, Ontario, Canada
- Facility name not stated
Oshawa, Ontario, Canada
- Facility name not stated
Sarnia, Ontario, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2013
- Primary completion
- 31 Jan 2015
- Completion
- 31 Jan 2015
- Last update posted
- 11 Nov 2015
- Registered enrollment
- 1,161
- Registry id
- NCT02008344
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.